New vaccine aims to fight breast cancer after standard treatment
NCT ID NCT04270149
First seen Feb 28, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This early-phase study tests a vaccine made from cancer-related peptides (protein pieces) to see if it is safe for people with ER-positive breast cancer. The vaccine is given after standard treatments like chemotherapy and is designed to train the immune system to recognize and attack cancer cells. Only 8 participants are enrolled, and the study focuses on safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.